After a very stagnant time in biotech M&A some deals emerging overnight.....
https://www.biopharmadive.com/news/johnson-johnson-ambrx-acquire-deal-antibody-drug-conjugate-prostate/703867/
In the cancer area, but at least some decent M&A activity. Those poor investment bankers are going hungry:
https://www.copyright link/wealth/investing/deal-making-languishes-at-decade-low-on-private-equity-drought-20230928-p5e8e1
(AFR)
PAR. SP, page-560
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 25.0¢ | $36.40K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40816 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 44646 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |